Rakovina CSO to Present at Tuscany Retreat on Cancer Research
Rakovina Therapeutics’ Chief Scientific Officer, Dr. Mads Daugaard, presented at the 13th Tuscany Retreat on Cancer Research and Apoptosis,...
eClinical Tech News
New Reduce-It® & EPA Data at ESC Congress 2025
Amarin Corporation is showcasing new data on icosapent ethyl (IPE), branded as Vascepa/Vazkepa, at the European Society of Cardiology...
Collegium Presents Real-World Data at PainWeek 2025
Collegium Pharmaceutical is leveraging the upcoming PAINWeek 2025 conference to showcase a significant body of real-world data (RWD) supporting...
Biogen & Stoke Announce Zorevunersen Data for Dravet Syndrome at Epilepsy Congress
Biogen and Stoke Therapeutics have presented encouraging 3-year open-label extension (OLE) data for zorevunersen, an antisense oligonucleotide (ASO) for...
Terumo Expands into Organ Transplantation with Organox Acquisition
Terumo Corporation’s acquisition of Organox for $1.5 billion marks a significant leap into the organ transplantation sector, a market...
Leqembi Launches in Austria and Germany, First in EU
Lecanemab, co-marketed by Eisai and Biogen as Leqembi®, has launched in Austria and is slated for imminent release in...
Biosyent Q2 & H1 2025 Financial Results Released
Biosyent Inc. reports robust financial results for Q2 and H1 2025, demonstrating continued growth across its Canadian pharmaceutical, international...
Iovance Grants Inducements Under Nasdaq Rule
Iovance Biotherapeutics, a leader in the burgeoning field of tumor-infiltrating lymphocyte (TIL) therapies, recently granted stock options to 20...
EU Approves Lecanemab, Alzheimer’s Drug, Launches in Austria & Germany
Eisai and Biogen have launched Leqembi, their anti-amyloid beta monoclonal antibody, in Austria and Germany, marking the drug’s first...
Terumo Expands into Organ Transplant Sector with OrganOx Acquisition
Terumo Corporation’s acquisition of Organox for $1.5 billion marks a significant leap into the burgeoning organ transplantation sector. This...